MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

Autor:	John Mascarenhas, Claire Harrison, Jean-Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro M. Vannucchi, Tymara Berry, Denise Redding, Laurie Sherman, Souria Dougherty, Lixian Peng, Libo Sun, Fei Huang, Ying Wan, Faye Feller, Srdan Verstovsek
Rok vydání:	2022
Předmět:	Immunology Cell Biology Hematology Biochemistry
Zdroj:	Blood. 140:6826-6829
ISSN:	1528-0020 0006-4971
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::05b45c4cdad5448742c798b15ec4cb68 https://doi.org/10.1182/blood-2022-160364 Zobrazit plný text záznamu